Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
Sponsor: Bambusa Therapeutics
Summary
This is a Phase 1, randomized, blinded, placebo controlled, single ascending dose (SAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
Official title: A Randomized, Blinded, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 in HVs and AD Patient
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
63
Start Date
2025-08-09
Completion Date
2027-03-26
Last Updated
2025-11-20
Healthy Volunteers
Yes
Conditions
Interventions
BBT001
BBT001 will be administered
Placebo
Placebo will be administered
Locations (10)
The Second Hospital of Anhui Medical Univesity
Hefei, Anhui, China
The Second Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Wuxi Second People's Hospital
Wuxi, Jiangsu, China
Jiangsu University Affiliated Hospital
Zhenjiang, Jiangsu, China
Jiangxi Provincial Dermatology Hospital
Nanchang, Jiangxi, China
Shandong Provincial Hospital for Skin Diseases
Jinan, Shandong, China
Shanghai Dermatology Hospital
Shanghai, Shanghai Municipality, China